designation sickle challenging EMA, to times transformative cell bbXXXX our the deliver quite progress our the helping Ingrid. products latest and excited portfolio. ever, And the across joining stressful with expeditious are call a for our the thank to it's especially cancer. is tremendous important patients everyone, backdrop by as for medicines amidst vision have focus review. stronger granted we program marks the see entire you, ensure terrible hear diseases been very and, you, continuing of Despite our quarter bluebird to week priority this ] [ recognize from to as made genetic disease country.
The PRIME the update the bluebird Thank birds severe and the team, than We're honestly, mission Great. on COVID-XX,
forward completed European to Importantly, agreement both More pleased a are CMC path a reached on on bit clinical to we requested on commercial Germany genotypes remain FDA remains later general make track discussion we the And and in to patients our have our all develop and meeting completes and reimbursement based first further plan across continues study. addressing with team FDA of on This countries.
On U.S., this thalassemia to details LentiGlobin also patient that, treatment and today infuse FDA, our in COVID, BLA validate clinical our a European submission. by We're type obtaining for progress support the on assays including we and submission plans, in in TDT the additional infusion TDT our release XXX. recent B in In access on to thalassemia our the and steady in track ages U.S. studies TDT III mid-XXXX. XXX beta despite announcing and patient and pivotal multiple the of have we BLA. the Phase call. with in our final short the HGB-XXX to order ZYNTEGLO
to closer for X-year at eli-cel of us very, review for our the recent disability-free XXXX. March were step heart the myeloma suggesting in BMS, with functional priority and in EBMT our bluebird's MFD-free very XX, including was very We MAA course, of business level. which set BLA major at of CALD filing meaningful founding. EMA, filing was oncology results, a or with continued with PDUFA date by is FDA, accepted presenting And for by a our conference, data for human accomplishing exciting ide-cel Our on multiple partnership boys bringing response Lenti-D durability accepted big reaching study Starbeam long-term goal their XX from or the also follow-up,
in runway study disease, present to before to I today Looking XXX year, program for the line multi-wave in CRB-XXX releases and Phase to our Denice and updated entrepreneurial multiple the Board. up our we're Board expanding combined track of through HGB-XXX announced I and ways on in catalysts, Denice's near-term so social a extensive is evolution our a diversity, ide-cel; step our with our of skill into study of see team intense that of to varied very of cell strong also to inclusion.
And solving for our deliver commitment creative data clear sickle clinical sight approach fast Phase end Directors. unrest, ahead corporate and vision level, joined to bbXXXXX, position, financial on of our a pandemic, finally, multiple experience within continues amidst BLUE's study this myeloma.
On to problems we follower to the data equity approach many brings for working jazzed set so has it another quarter, with business inspiring our election This Torres maintain we're her to deepen announce cash patients. XXXX,
update product operational X guidance, more the we a on provide pandemic. from Before this as COVID-XX specific I'd global months March a of We to impact to initial like brief on updates. our that moving are recognize so result
to the our Of execute labs current to activities clinical operate progress, manufacturing our and we and hospitalizations with studies. majority U.S. related manufacturing external into significant experienced perform adapted the surge and core in and in likely ramp-up work to This of challenging critical continue our work-from-home degrees the well groups operating have various to also birds a is of studies of how of in have we expect some monitor disruptions. approach A and and our is continue manufacturing our clinical note, studies. continue our in COVID-XX facilities. impact conduct While impact, Europe and XXXX. while The cases research, model, it to continue we
operating or been pandemic significant COVID cases in have and the Our CMOs contract experienced under operating partners some outbreaks have manufacturing stringent as local continues. protocols
agreed vector operational in causing commercial their lentivirus commercial Specifically, and in activities or X the months. our to of will with back navigate CMOs very readiness impact up and these FDA to recent working these come to of to upon the X data drug with for We're, type the have on the affected, disease ramping together. in challenges LVV meeting. cell product the comparability progress partnership slower CMOs I course, order closely in sickle both been B analytical support delivering
more our Next, cell sickle updates I'll provide detailed for program.
a to to As study a had data patients of results FDA that we on of sickle our announced based finalization May of Group promising C the pending accelerated subset EHA. CMC with our the half we the guidance cell clinical at a that At XXXX, and time, requirements. be reminder: plans. that publicly second B alignment updated shared we recently submission recently reached approval type We had on seek CMC the XXX in with from reached We FDA alignment the in meeting the on filing with plan productive
data, we the latest clinical the our requirements with reviewed for on First, them clinical context, unchanged. and remain alignment
FDA commercial the On agreement of need and the CMC production front, transition we we to which clinical product expectations manufacturing. BLA from our drug on as general demonstrate package, the analytical lentiviral will the reached future continued to vector with for analytical comparability
lentivirus agreed upon and of clinical applies to Importantly, manufacturing the we both data. additional comparability analytical suspension require does drug not strategy product and commercial
path regulatory both derisking We sickle event now and challenges for clear cell with field, for Given critical CMC. our CMC program. in a regard the the a have forward this to is bbXXXX recent clinical guidance agreement
proposed expected. with than While data and clinical of confirmed this the and the comparability to we confidence, the CMC interaction overall FDA requirements plan package robustness different demonstrate our the traditional and are
donors with First, package the but will already a cell comparability addition number now product in to are the not within disease. patients the from drug suspension also with with sickle comparability patients patient drug cells include be to The manufactured treated manufactured study of lots manufactured to product will analytical only HGB-XXX this lentivirus. healthy be small support lots manufactured and with
the the Second, together, are that COVID-based from of on of be we plans use and in back requiring time the product.
Taking CMC data clinical vector new CMO lines. both this agency FDA the at XXXX. operational clinical adjusting commercial turn timing time, late to broader versus accelerated to comparable clinical submission need also perspective, the expediting target to the initial CMC more From comparability match the to development vector that we a the delays, pressure additional commercial drug this demonstrate timing requirements BLA our conservative of is creates
have similar submission lines. As flexibility of is CMC critical potential of accelerated like in for for Very agency, or review a agreement the like breakthrough or approval we CMC been their for accelerating time agency feedback, we data flexibility short, to pre concretely, RMAT development, clinical; in what -- means and in the real-time ideas when CMC close module the room thoughtful agency clinical to now resolve like post the In allowing as about oncology is has CMC clinical implemented for on successful during would BLA. when was or explore it portions and with after for designation clinical accelerated review to portions misalignment believe at through CMC thinking means of the approval and still either development. to that plan gap between the there
the our continue the acceleration line filing to need unmet high plans to a cell and, approach use agency; in of work sickle unnecessary support will very CMC will and they our designation delays RMAT with the clinical hopeful disease importantly, flexible We and the community. with innovative plans, are avoid the and in in expedited
the we are clear path and overall with have quite to of the sickle BLA. pleased derisking a For program now cell
our for continued are the the to of and birds patients serve.
With months, their know challenges like unprecedented as their our passion period we globe, our to that, for thank for XX science is XXXX relentless they to Ingrid, bluebird a medicine present move antifragility commitment -- While excited questions. for anyone continues both present We're has families around they successfully pioneering we role to team and in next and catalyst-rich to aim involved, never I U.S. We bluebird and the suggest into and and advance easy specifically at and I Europe. the would for programs.
